Among IBD patients, corticosteroid use has been associated with an increased risk of VTE, whereas anti-TNF therapy does not appear to increase this risk. High-dose tofacitinib has also been shown to increase the likelihood of VTE in patients with additional risk factors. In order to prevent future VTE events, pharmacologic thromboprophylaxis should be emphasized, particularly in hospitalized IBD patients, with recent data suggesting that a select population at risk may benefit from continued prophylaxis.
Keyphrases
- venous thromboembolism
- direct oral anticoagulants
- high dose
- risk factors
- end stage renal disease
- ulcerative colitis
- rheumatoid arthritis
- ejection fraction
- chronic kidney disease
- newly diagnosed
- low dose
- prognostic factors
- peritoneal dialysis
- machine learning
- stem cells
- cell therapy
- patient reported outcomes
- mesenchymal stem cells
- big data
- artificial intelligence
- replacement therapy